SCHAUMBURG, IL January 7, 2005 American Pharmaceutical Partners, Inc. (NASDAQ:APPX) and American Bioscience, Inc. (ABI) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRAXANETM for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer. ABRAXANE^TM is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

The approval marks a new class of "protein-bound particle" drugs, now made possible by ABI's proprietary nanoparticle albumin-bound (nab^TM) technology. ABRAXANE is the first in this new class of drugs.

ABRAXANE, consisting only of albumin-bound paclitaxel nanoparticles, is free of toxic solvents and demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with the solvent-based Taxol in a prospectively randomized trial of 460 patients with metastatic breast cancer. Because it contains no toxic solvents, this next-generation taxane product enables the administration of 50% more chemotherapy with a well-tolerated safety profile, requires no premedication to prevent hypersensitivity reactions and can be given over 30 minutes using standard IV tubing.

"ABRAXANE provides a much-needed new treatment option for women with metastatic breast cancer," said principal clinical trial investigator William J. Gradishar, M.D., Associate Professor of Medicine, Division of Hematology and Medical Oncology and Co-Director, Lynn Sage Breast Cancer Program at Northwestern Memorial Hospital. "The pivotal clinical trial results demonstrated that ABRAXANE had superior response rate when compared to Taxol in patients with metastatic breast cancer. For the first time we are ab
'"/>

Contact: Shirley Johnson
sjohnson@healthstarpr.com
212-532-0909
HealthStar PR
7-Jan-2005

Page: 1 2 3 4 5 6 7 8 9
Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
6. DFG approves additional six research training groups
7. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
8. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
9. Researchers find stem-cell therapy effective in targeting metastatic cancer
10. CellSearch System cleared for monitoring metastatic breast cancer
11. Unique estrogen receptor linked to metastatic breast cancer